Long‑term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: Treatment persistence is differentially affected by disease phenotype, obesity and sex
Arthritis Research & Therapy 2025;27:202 Doi: 10.1186/s13075-025-03664-y
Data by Flouri et al. support greater drug persistence with secukinumab than with TNF inhibitors in patients with axSpA and peripheral spondyloarthritis, both with respect to efficacy- and safety-related discontinuations, while the achievement of 6-month treatment targets was comparable. Flouri et al. compared long term treatment persistence, efficacy and safety between secukinumab and TNF inhibitors in a cohort of patients with SpA treated in real life.
Differential persistence of biologic agents commonly used in SpA was seen in this real-life prospective study. Distinct effects of obesity, sex and specific spondyloarthritis diagnosis on persistence were also observed, which, if confirmed in other cohorts, could optimize clinical decision making and improve patient outcomes.
Keywords:
